Canary’s First-in-class Dual RNAi Gene Silencing Offers a Novel Approach to Weight Loss and Metabolic Disease Management
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing New York, November 18thth, 2024 – Canary Cure, a biotechnology company focused on developing innovative RNAi therapies, today announced the results of a diet-induced-obesity (DIO) mouse study demonstrating the potential of its first-in-class dual siRNA therapy, CCT-217, to […]
Canary Cure Advances Novel siRNA Therapeutic Targeting Obesity into In Vivo Trials
First-in-Class Gene-Targeted Approach to Promote Fat-Burning, Preserve Lean Body Mass, and Enhance Metabolic Health by Harnessing the Endocannabinoid System
Canary Global Approved for Canada’s SR&ED Program for Advancing Science and Technology
Canary Global has been accepted into Canada’s SR&ED program which aims to encourage R&D work conducted for the advancement of scientific knowledge or for the purpose of achieving a technological advancement.Canary applied to be included in the program in order to advance its microRNA (miRNA) work which it began during the COVID epidemic. The company […]
